BiVACOR Total Artificial Heart (TAH)

About BiVACOR

BiVACOR is developing a next-generation Total Artificial Heart (TAH) that represents a significant technological leap over existing volume-displacement devices. Its key innovation is a single, magnetically levitated rotor that simultaneously pumps blood to both the lungs and body, aiming for greater durability, smaller size, and improved physiologic control. The company achieved a major milestone in July 2024 with its first-in-human implant as part of an FDA-approved Early Feasibility Study, positioning it as a leader in the advanced heart failure device space. With heart transplant availability severely limited, BiVACOR's TAH targets a large and growing unmet need for patients with end-stage biventricular failure.

Therapeutic Areas